| |
|
|
|
| You Are Here:
Mesothelioma.net Blog > 2009 > September |
|
Archive for September, 2009
Wednesday, September 30th, 2009
Japanese scientists may have discovered a more accurate way to diagnose mesothelioma with the creation of a device called the IT knife. The IT knife, an insulated-tip diathermic knife, is a special kind of tool that uses heat to cauterize a large piece of diseased tissue.
Because mesothelioma can remain undetected for so long (anywhere from 20-50 years) and because of it’s location in the patient’s body, often times medical professionals have trouble identifying whether or not the disease is actually mesothelioma, or a different lung disease all together like emphysema, bronchitis, or chronic obstructive pulmonary disease (COPD).
During this new procedure, after fluids are taken and analyzed from the pleural cavity, a biopsy is done using the IT knife rather than the traditional standard flexible forceps (SFF) to collect tissue samples for lab work and testing.
Not only is the IT knife biopsy performed quickly with no severe complications, studies show that the IT knife was 25% more likely to provide the information needed to establish a mesothelioma diagnosis than the SFF. Additionally, the IT knife biopsy was better than SFF in eight of the 20 cases – three of which had malignant pleural mesothelioma.
Because the piece of tissue capable of being collected by the IT knife is larger in size than the small piece normally collected with the SFF, the IT solution allows more information to be gathered and a more precise diagnosis to be made. This is good news for patients who need to begin immediate treatment for what is most likely an advanced stage of cancer.
Tags: mesothelioma, mesothelioma research Posted in News | No Comments »
Tuesday, September 29th, 2009
Medical professionals may now be able to give a more accurate prognosis to patients with mesothelioma than ever before.
Research is ongoing to find better ways to diagnose and treat mesothelioma. For example, one study recently published by Italian scientists demonstrates that the presence of a protein called placental growth factor (PlGF) can actually help determine both the prognosis and the best course of treatment for mesothelioma patients.
What is PIGF?
PIGF is a protein normally found in very high levels in both the cells of developing placentas and in mesothelioma cells. It seems to have an influence on the survival of malignant tumors.
PlGF is also related to vascular endothelial growth factor (VEGF), which has been shown to encourage the growth of new blood vessels. These blood vessels can also feed tumors.
Not only can stopping the development of the VEGF induced blood vessels slow down the growth of tumors relying on the new blood vessels to provide it nutrients, a better prognosis can now be predicted since the studies also show that higher PlGF levels in mesothelioma patients resulted in shorter survival time after invasive surgery, and lower levels of the same protein indicated longer survival times.
While there is no cure for mesothelioma, PlGF shows promise as a diagnostic tool to determine the prognosis of mesothelioma patients, as well as a potential avenue for new mesothelioma treatments.
Tags: mesothelioma, mesothelioma research, mesothelioma treatment Posted in News | No Comments »
Monday, September 28th, 2009
Researchers and scientists in Greece have announced results of a single institution Phase II study which tested a new possible treatment for mesothelioma. There was encouraging success according to a recently publicized report.
Researchers from the Athens University School of Medicine in Greece tested the effectiveness of gemcitabine plus docetaxel as a chemotherapy option.
Standard treatment for malignant pleural mesothelioma is combinations of Alimta (permetrexed) and Cisplatin (gemcitabine). This study was to examine the efficacy of the new combination Cisplatin (gemcitabine) and Taxotere (docetaxel) in the first-line setting. This combination has not been investigated before.
Of the twenty-five patients who suffer from malignant pleural mesothelioma and participated in the trial, seven responded to the treatment. They received 80 mg of docetaxel and 1,000 mg of gemcitabine on days 1 and 4 of a 28-day cycle.
The treatment was scheduled for a maximum of 6 cycles or until the disease showed signs of progression or unacceptable toxicity became present. These seven patients’ tumors shrunk in size. For fourteen of the patients there was no change in tumor size and the remaining four patients had tumors increase in size.
The researchers concluded the administration of gemcitabine and docetaxel appears to be promising first-line therapy for patients with mesothelioma. It is well tolerated and appears to improve survival.
Tags: mesothelioma, mesothelioma research, mesothelioma treatment Posted in News | 1 Comment »
Saturday, September 26th, 2009
Today is National Mesothelioma Awareness Day, a yearly event that seeks to raise the public’s understanding of mesothelioma, asbestos exposure, and the lack of funding for mesothelioma research and treatment.
The day, begun in 2005 by a group of volunteers working for the Mesothelioma Applied Research Foundation and who had been personally affected by mesothelioma, will include local events in more than 20 cities and radio spots on more than 100 stations across the country.
The radio announcements will begin with music by well known singer-songwriter Warren Zevon, who died from mesothelioma in 2003. A short segment about mesothelioma will follow. Despite his heavy smoking habit, Devon was very healthy and hadn’t visited a doctor in over 20 years before being forced to be seen by a nagging cough and chest pain. He was diagnosed with an advanced stage of pleural mesothelioma and few treatment options were available to him.
Because the disease is relatively rare, research for a cure is under funded. When diagnosed, victims are told there is no cure and mesothelioma treatments such as chemotherapy, radiation and surgery at best only slow the spread of the disease. A few experimental treatments such as immunotherapy, gene therapy, photodynamic therapy and anti-angiogenesis therapy offer hope of a cure in the future, but more research is needed.
To learn more about how you can help raise awareness in your area, visit the National Mesothelioma Awareness Day webpage.
Tags: mesothelioma, mesothelioma research Posted in News | No Comments »
Thursday, September 24th, 2009
Rosetta Genomics, Ltd., a leading developer of microRNa-based molecular diagnostics, and Super Religare Laboratories Limited (SRL), India”s largest diagnostics network, have announced they have signed an exclusive distribution agreement for Rosetta”s three diagnostic tests, including a test for mesothelioma.
The agreement allows SRL to market Rosetta tests in India, Saudi Arabia, Qatar and the United Arab Emirates (UAE).
MicroRNas are gaining immense importance in the field of diagnostics and targeted therapy. The novel concept of microRNA based molecular signatures for identifying or characterizing cancer types is rapidly gaining acceptance in clinical practice.
One of the tests, the miRview meso, leverages microRNAs specificity as biomarkers to differentiate mesothelioma from other carcinomas in the lung. Mesothelioma patients need to begin treatment as soon as possible, so receiving an accurate diagnosis is very important. miRview meso is a very accurate test that allows physicians to make a more specific diagnosis.
Tags: mesothelioma Posted in News | No Comments »
|
|
|
|
|
|